Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000007110
JPRN-UMIN000007110
Completed
未知

Analysis of Rituximab intensification therapy for low grade B-cell lymphoma refractory to Bendamustine - Bendamustine intensification therapy for low grade B-cell lymphoma refractory to Bendamustine

Tokyo women's medical university0 sites50 target enrollmentJanuary 27, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Tokyo women's medical university
Enrollment
50
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 27, 2012
End Date
January 1, 2020
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Tokyo women's medical university

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\. for whom Bendamustine is contraindication 2\. with liver cirrhosis 3\. with severe mental disability 4\. pregnant or possible to be pregnant

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTPTHROMBOTIC THROMBOCYTOPENIC PURPURAMedDRA version: 9.1Level: LLTClassification code 10037562
EUCTR2010-018794-38-ITFONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
Active, not recruiting
Phase 1
Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study. - REOVAS
EUCTR2016-000275-25-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)108
Completed
Phase 2
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating Polyneuropathy
JPRN-UMIN000035753agoya University Hospital27
Completed
Phase 2
RECIPE Trial
JPRN-jRCT2041180037Iijima Masahiro25
Completed
Phase 2
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)Diffuse large B-cell lymphoma
JPRN-UMIN000001050Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)40